


Product Name : Trilaciclib
Cat. No. : PC-60395
CAS No. : 1374743-00-6
Molecular Formula : C₂₄H₃₀N₈O
Molecular Weight : 446.55
Target : Cyclin-dependent Kinase (CDK)
Solubility : 10 mM in DMSO



Biological Activity

Trilaciclib (G1T28) is a novel, potent and selective inhibitor of **CDK4/6** with biochemical IC₅₀ of 1 nM and 4 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.

Trilaciclib (G1T28) displays >30-fold selectivity for CDK4/cyclin D1 over CDK2/cyclin A, CDK2/cyclin E, CDK5/p25, CDK5/p35, and CDK7/cyclin H/Mat1, 50-fold over CDK9/cyclin T.

Trilaciclib (G1T28) reversibly pauses the cell cycle in the G1 phase in CDK4/6-dependent cell lines, protects CDK4/6-dependent cells from chemotherapy-induced damage in vitro.

Trilaciclib (G1T28) induces a reversible cell-cycle arrest in murine and canine HSPCs; attenuates chemotherapy-induced myelosuppression in vivo.

References

Bisi JE, et al. *Mol Cancer Ther.* 2016 May;15(5):783-93.

He S, et al. *Sci Transl Med.* 2017 Apr 26;9(387). pii: eaal3986.

Stice JP, et al. *Mol Cancer Res.* 2017 Jun;15(6):660-669.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com